Second-line Immunotherapy for ES-SCLC

NCT06853678 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Interventions

DRUG: Adebrelimab
DRUG: Selinexor
DRUG: Nab-paclitaxel

Sponsor

Tianjin Medical University Cancer Institute and Hospital